Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

By R. Motzer, B. Escudier, S. Oudard, Thomas E. Hutson, F. T. 4. Group. The Lancet, 2008

2,970 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ceb8ea8e3ee9b1801cd9ffdf73f00290541e926e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Physiology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. (2010, background): “In addition, further therapy will include agents with proven antitumor activity in the treatment-refractory setting, extending control of tumor burden and thus OS.(13,27,28) The fact that other contemporary phase III trials, including trials investigating sunitinib and sorafenib and the other phase ”
Systemic therapy in metastatic renal cell carcinoma (2016, background): “An advantage in PFS could be demonstrated for the treatment with everolimus [25, 26].”
The PI3K/AKT Pathway as a Target for Cancer Treatment. (2016, background): “In a second trial, everolimus was associated with improved progression-free survival (PFS) compared with best supportive care in patients with metastatic renal disease previously exposed to sunitinib or sorafenib (63).”
Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010, methodology): “Sensitivity analyses indicated that benefit was maintained across subgroups and was consistent with the interim analysis (data not shown).(3) Investigator-assessed data demonstrated a median PFS of 5.”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Indeed, the use of everolimus increased PFS in patients with metastatic renal cell carcinoma who became refractory to VEGFA-targeted therapies 146 .”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “40) 3 [128]”
Targeting the cancer kinome through polypharmacology (2010, neutral): “Smaller but significant responses have been observed for some cancers that are highly dependent on angiogenesis, and therefore sensitive to inhibitors of vascular endothelial growth factor (VEGF) signalling, such as renal cell carcinoma 8–11 .”